Heterocyclic inhibitors of glycogen synthase kinase GSK-3

Details Heterocyclic inhibitors of glycogen synthase kinase GSK-3 Heterocyclic inhibitors of glycogen synthase kinase GSK-3

2005-03-29

2005-03-29

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S351000, C548S128000, C548S129000

Reexamination Certificate

active

06872737

ABSTRACT:
Compounds of general formula (I):where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

REFERENCES:
patent: 3374240 (1968-03-01), Ottman et al.
patent: 3534057 (1970-10-01), Krenzer
patent: 3900485 (1975-08-01), Krenzer
patent: 4183816 (1980-01-01), Gavin et al.
patent: 4420522 (1995-12-01), None
patent: 0 711 773 (1996-05-01), None
patent: 58216177 (1983-12-01), None
patent: WO 9517182 (1995-06-01), None
patent: WO 0021927 (2000-04-01), None
patent: WO 0038675 (2000-07-01), None
patent: WO 0109106 (2001-02-01), None
Jha et al., 1998, “Donor behavior of isoperthiocyanic acid..”, CAS:128:96805.*
Groutas et al., 1994, “Substituted 3-oxo-1,2,5-thiadiazolidine 1, 1-dioxides..”, CAS:120:124451.*
Marcinkeviciene et al. , 2000, Biochemical Pharmacology, “Selective inhibition of bacterial dihydroorotate..”, 60:339-342.*
Heuer et al., 1996, “Bactericidal thiadiazolidinedione.”, CAS:124:48317.*
English-translated version of DE 4420522, and a comment from USPTO Germanic language translator, dated May 4, 2004.*
Martinez et al., “Synthesis and Potential Muscarinic Receptor Binding and Antioxidant Properties of 3-(Thiadiazolyl)pyridine 1-Oxide Compounds”Arch. Pharm. Pharm. Med. Chem., vol. 332,pp. 191-194 (1999).
Martinez et al., “Arylimino-1,2,4-Thiadiazolidinones: A New Family of Potassium Channel Openers”,Bioorganic&Medicinal Chemistry, vol. 5, No. 7, pp. 1275-1283 (1997).
Slomczynska et al., “Efficient Synthesis of 1,2,4—Dithiazolidine-3,5-diones (Dithiasuccinoyl-amines) and Observation on Formation of 1,2,4—Thiadiazolidine-3,5-diones by Related Chemistry”,J. Heterocyclic Chem., vol. 21, pp. 241-246 (1984).
STN Registry No.: 89570-37-6.

Affiliated with

Also associated with

Rating

Heterocyclic inhibitors of glycogen synthase kinase GSK-3 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic inhibitors of glycogen synthase kinase GSK-3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of glycogen synthase kinase GSK-3 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3398678